Clinical Trials in France / NCT06780475
Recruiting
Observational
Validation of in Vitro Method for Anti-MCPyV Immunotherapy on Patients With Cutaneous Merkel Cell Carcinoma
NCT06780475 · tracked via the Priya Life Science France tracker
Condition(s) studied
Merkel Cell Carcinoma of Skin
Study summary
The aim of the study is to test and validate in vitro a cell therapy approach for MCPyV+ Merkel Cell Carcinoma patients.
Eligibility
Inclusion Criteria:
* Patients \>= 18 years old;
* Diagnosed with Merkel cell carcinoma of skin, ongoing for local treatment, systemic treatment, complementary treatment or an active follow-up;
* Informed for the study and no-opposed for participation;
* Affiliated with a social security scheme or in an equivalent situation.
Exclusion Criteria:
* Patients ongoing another interventional clinical trial;
* Patients under guardianship or trusteeship;
* Pregnancy or breastfeed;
* Patients refusal.
Primary outcome measure(s)
- Anti-MCPyV functionality — Day 0 and Day 4
Anti-MCPyV functionality, including cytotoxicity, of T cells obtained after in vitro culture.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Dermato-oncology Department, Ambroise Paré Hospital, APHP | Boulogne-Billancourt | France | Recruiting |
More Assistance Publique - Hôpitaux de Paris trials in France
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06780475 on ClinicalTrials.gov ↗ ← All trials in France